[ CAS No. 31555-59-6 ] {[proInfo.proName]}

Name: 31555-59-6|5-Methylthiophene-2-carbonyl chloride|95%
Brand: Ambeed
SKU: A322472
Rating: 99 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

DV 2D 3D

3d Animation Molecule Structure of 31555-59-6

Structure of 31555-59-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 31555-59-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 31555-59-6 ]

SDS Specification

Alternatived Products of [ 31555-59-6 ]

Product Details of [ 31555-59-6 ]

CAS No. :	31555-59-6	MDL No. :	MFCD00130092
Formula :	C₆H₅ClOS	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	DJCGIWVUKCNCAT-UHFFFAOYSA-N
M.W :	160.62	Pubchem ID :	2760083
Synonyms :

Calculated chemistry of [ 31555-59-6 ]

Physicochemical Properties

Num. heavy atoms :	9
Num. arom. heavy atoms :	5
Fraction Csp3 :	0.17
Num. rotatable bonds :	1
Num. H-bond acceptors :	1.0
Num. H-bond donors :	0.0
Molar Refractivity :	39.47
TPSA :	45.31 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.26 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.93
Log Po/w (XLOGP3) :	2.85
Log Po/w (WLOGP) :	2.44
Log Po/w (MLOGP) :	1.37
Log Po/w (SILICOS-IT) :	3.46
Consensus Log Po/w :	2.41

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.98
Solubility :	0.17 mg/ml ; 0.00106 mol/l
Class :	Soluble
Log S (Ali) :	-3.46
Solubility :	0.0557 mg/ml ; 0.000347 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.61
Solubility :	0.397 mg/ml ; 0.00247 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.17

Safety of [ 31555-59-6 ]

Signal Word:	Danger	Class:	8
Precautionary Statements:	P233-P260-P261-P264-P271-P280-P301+P330+P331-P302+P352-P303+P361+P353-P304-P304+P340-P305+P351+P338-P310-P312-P321-P332+P313-P337+P313-P340-P362-P363-P403-P403+P233-P405-P501	UN#:	1760
Hazard Statements:	H314-H315-H319-H335	Packing Group:	Ⅱ
GHS Pictogram:

Application In Synthesis of [ 31555-59-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 31555-59-6 ]

[ 31555-59-6 ] Synthesis Path-Downstream 1~88

1
[ 188290-36-0 ]
[ 31555-59-6 ]
[ 56824-83-0 ]

Reference： [1]Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1956,p. 992,998;engl.Ausg.S.1013,1018

2
[ 554-14-3 ]
[ 31555-59-6 ]
[ 99845-90-6 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1949,vol. 68,p. 5,29
[2]Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1956,p. 1361,1368; engl. Ausg. S. 1395, 1401

3
[ 31555-59-6 ]
[ 92-88-6 ]
4,4'-Bis(5-methyl-2-thienylcarbonyloxy)biphenyl [ No CAS ]

Reference： [1]Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie,1983,vol. 38,p. 1669 - 1677

4
[ 31555-59-6 ]
[ 57-88-5 ]
5-Methyl-2-thiophencarbonsaeurecholesterylester [ No CAS ]

Reference： [1]Zeitschrift fur Naturforschung, Teil B: Anorganische Chemie, Organische Chemie,1983,vol. 38,p. 1669 - 1677

5
[ 31555-59-6 ]
[ 1177-87-3 ]
[ 83880-83-5 ]

Reference： [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 1581 - 1588

6
[ 31555-59-6 ]
[ 123-30-8 ]
5-Methyl-thiophene-2-carboxylic acid (4-hydroxy-phenyl)-amide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1984,vol. 27,p. 1347 - 1350

7
[ 31555-59-6 ]
[ 60779-19-3 ]
2-[2-Hydroxy-5-(5-methyl-thiophene-2-carbonyl)-phenyl]-propionic acid methyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 1663 - 1668

8
[ 31555-59-6 ]
[ 27031-76-1 ]
[ 83880-82-4 ]

Reference： [1]Journal of Medicinal Chemistry,1987,vol. 30,p. 1068 - 1073

9
[ 31555-59-6 ]
[ 99-96-7 ]
[ 132215-48-6 ]

Reference： [1]Molecular Crystals and Liquid Crystals (1969-1991),1990,vol. 193,p. 167 - 170

10
[ 31555-59-6 ]
[ 41355-50-4 ]
N-(2,3,4,6-tetra-O-acetyl-α/β-D-glucopyranosyl)-5-methylthiophene-2-carboxamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1316 - 1319

11
[ 31555-59-6 ]
[ 542-92-7 ]
{5-[1-Hydroxy-1-(5-methyl-thiophen-2-yl)-meth-(Z)-ylidene]-cyclopenta-1,3-dienyl}-(5-methyl-thiophen-2-yl)-methanone [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2005,vol. 127,p. 15010 - 15011

12
[ 31555-59-6 ]
[ 41355-50-4 ]
N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-5-methylthiophene-2-carboxamide [ No CAS ]
N-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-5-methylthiophene-2-carboxamide [ No CAS ]

Reference： [1]Carbohydrate Research,2006,vol. 341,p. 1370 - 1390

13
[ 934235-75-3 ]
[ 31555-59-6 ]
[ 1027322-96-8 ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1347 - 1353

14
[ 31555-59-6 ]
[ 38093-77-5 ]
5-methylthiophene-2-carboxylic acid (2,4-diphenylthiazol-5-yl)amide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With pyridine; In dichloromethane; at 20℃; for 18h;	5-Methylthiophene-2-carboxylic acid (2,4-diphenylthiazol-5-yl)amide (1 r).5-Methylthiophene-2-carboxylic acid (213 mg, 1 .50 mmol) was suspended in DCM (5.0 mL) then oxalyl chloride (131 muL, 1 .50 mmol) and DMF-DCM (1 :9, 20 muL) was added. After stirring at ambient temperature for 1 h, a solution of 2,4-diphenyl-5-aminothiazole (252 mg, 1 .00 mmol) in pyridine (5.0 mL) was added and stirring of the resultant mixture continued at ambient temperature for 18 hours. The reaction mixture was diluted with DCM (60 mL) and washed successively with 1 M HCI (4 x 40 mL) and sat. NaHCO3 (2 x 40 mL). The organic layer was dried over MgSO4, filtered and evaporated giving crude material, which was purified by flash column chromatography on silica gel, eluted with 60-75% DCM-hexane, yielding 1 r as an off-white solid (252 mg, 67%). mp 1900 C; m/z (El), 376 (M+); HRMS, found 376.0695 (C21 H16N2OS2, M+, requires 376.0704).

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1347 - 1353
[2]Patent: WO2008/90382,2008,A1 .Location in patent: Page/Page column 44

15
[ 31555-59-6 ]
[ 313527-44-5 ]
C₂₀H₁₆N₂O₂S [ No CAS ]

Reference： [1]European Journal of Medicinal Chemistry,2007,vol. 42,p. 1293 - 1299

16
[ 31555-59-6 ]
5-methylthiophene-2-carboxylic acid (2,4-diphenyloxazol-5-yl)amide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1347 - 1353

17
[ 31555-59-6 ]
1,3-bis(5-methylthien-2-yl)-4H-cyclopenta[c]thiophene [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2005,vol. 127,p. 15010 - 15011

18
[ 31555-59-6 ]
N-(β-D-glucopyranosyl)-5-methylthiophene-2-carboxamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1316 - 1319

19
[ 31555-59-6 ]
5-Methyl-thiophene-2-carboxylic acid ((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yl)-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 1316 - 1319

20
[ 31555-59-6 ]
4-[2-methyl-4-(5-methyl-thiophen-2-yl)-oxazol-5-yl]-benzenesulfonamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

21
[ 31555-59-6 ]
acetic acid 1-(4-<i>tert</i>-butylsulfamoyl-phenyl)-2-(5-methyl-thiophen-2-yl)-2-oxo-ethyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

22
[ 31555-59-6 ]
2-fluoro-4-[2-methyl-4-(5-methyl-thiophen-2-yl)-oxazol-5-yl]-benzenesulfonamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

23
[ 31555-59-6 ]
[ 415679-07-1 ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

24
[ 31555-59-6 ]
[ 415679-13-9 ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

25
[ 31555-59-6 ]
acetic acid 1-(4-<i>tert</i>-butylsulfamoyl-3-fluoro-phenyl)-2-(5-methyl-thiophen-2-yl)-2-oxo-ethyl ester [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2002,vol. 45,p. 1511 - 1517

26
[ 31555-59-6 ]
[ 180302-54-9 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 65 - 68

27
[ 31555-59-6 ]
4-(4-methanesulfonyl-phenyl)-2-methyl-5-(5-methyl-thiophen-2-yl)-oxazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 65 - 68

28
[ 31555-59-6 ]
5-(4-methylsulfonylphenyl)-2-methyl-4-(5-methyl-thien-2-yl)oxazole [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 65 - 68

29
[ 31555-59-6 ]
4-[(5-methyl-thiophene-2-carbonyl)-amino]-benzoic acid [ No CAS ]

Reference： [1]Medicinal Chemistry Research,1998,vol. 8,p. 291 - 304

30
[ 31555-59-6 ]
4⁽⁵⁾-(5-methylthiophen-2-ylmethyl)-1H-imidazole [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 863 - 872

31
[ 31555-59-6 ]
[ 1027664-53-4 ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 863 - 872

32
[ 31555-59-6 ]
[ 334917-71-4 ]

Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 863 - 872

33
[ 31555-59-6 ]
5-Methyl-thiophene-2-carboxylic acid (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl)-amide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 493 - 498

34
[ 31555-59-6 ]
N-debenzoyl-N-(5-methyl-2-thenoyl)butitaxel [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1997,vol. 40,p. 236 - 241

35
[ 31555-59-6 ]
2-(5-Methyl-thiophen-2-yl)-3H-imidazo[4,5-c]quinoline [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1996,vol. 39,p. 2844 - 2851

36
[ 31555-59-6 ]
[ 91112-09-3 ]

Reference： [1]Journal of Medicinal Chemistry,1984,vol. 27,p. 1347 - 1350

37
[ 554-14-3 ]
[ 31555-59-6 ]

Reference： [1]Molecular Crystals and Liquid Crystals (1969-1991),1990,vol. 193,p. 167 - 170

38
[ 31555-59-6 ]
[ 99059-47-9 ]

Reference： [1]Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1956,p. 992,998;engl.Ausg.S.1013,1018

39
[ 31555-59-6 ]
(3-chloro-4-hydroxy-phenyl)-(5-methyl-[2]thienyl)-ketone [ No CAS ]

Reference： [1]Journal of the Chemical Society, 1054 1034, 1035, 1036,

40
[ 31555-59-6 ]
(3-bromo-4-hydroxy-phenyl)-(5-methyl-[2]thienyl)-ketone [ No CAS ]

Reference： [1]Journal of the Chemical Society, 1054 1034, 1035, 1036,

41
[ 13679-74-8 ]
[ 31555-59-6 ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1949,vol. 68,p. 5,29

42
[ 31555-59-6 ]
[ 4218-22-8 ]

Reference： [1]Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya,1956,p. 1361,1368; engl. Ausg. S. 1395, 1401

43
[ 31555-59-6 ]
[ 100715-89-7 ]

Reference： [1]Journal of the Chemical Society,1959,p. 3234,3235

44
[ 31555-59-6 ]
1-biphenyl-4-yl-1-(5-methyl-[2]thienyl)-2-phenyl-ethylene [ No CAS ]

Reference： [1]Recueil des Travaux Chimiques des Pays-Bas,1949,vol. 68,p. 5,29

45
[ 31555-59-6 ]
[ 84478-71-7 ]
C₁₆H₁₃ClFNO₂S [ No CAS ]

Reference： [1]Patent: US6337417,2002,B1 .Location in patent: Referential example 3

46
[ 31555-59-6 ]
1-(S)-[4-(3,4-dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropylamine [ No CAS ]
N-{1-(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-5-methylthiophene-2-carboxamide dihydrochloride salt [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Proceeding as described in Example 1, Steps 1-4 above but substituting L-Boc-valine in Step 3 with L-Boc-tert-leucine (commercially available from Fluka) gave 1-(S)-[4-(3,4-dichlorobenzyl)piperazin-1-ylcarbonyl]-2,2-dimethylpropylamine which was reduced to 1-(S)-[4-(3,4-dichloro-benzyl)piperazin-1-ylmethyl]-2,2-methylpropylamine (Step 5) and then reacted with: 4-Methylsulfonylbenzoyl chloride; 4-Acetoxybenzoyl chloride; 4-N,N-Dimethylaminobenzoyl chloride; 5-Methyl-2-thenoyl chloride; and 4-Methylbenzoyl chloride, to give N-{1(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-4-methylsulfonylbenzamide dihydrochloride salt, mp 190-191 C.; N-{1(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-4-acetoxybenzamide dihydrochloride salt, mp 241-242 C.; N-{1(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-4-N,N-dimethylaminobenzamide dihydrochloride salt, mp 101.5-105 C.; N-{1(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-5-methyl-2-thiophenecarboxamide dihydrochloride salt, mp 249-253 C.; and N-{1(S)-[4-(3,4-Dichlorobenzyl)piperazin-1-ylmethyl]-2,2-dimethylpropyl}-4-methylbenzamide dihydrochloride salt by following the procedure described in Steps 5 and 6 above.

Reference： [1]Patent: US6339087,2002,B1 .Location in patent: Page column 54

47
[ 31555-59-6 ]
[ 746669-24-9 ]
5-methyl-thiophene-2-carboxylic acid [6-(1-dimethylsulfamoyl-3-pyridin-2-yl-1H-pyrazol-4-yl)-quinazolin-4-yl]-amide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In acetonitrile;Heating / reflux;	To a solution of 200 mg (0. 5 mmol) of 4- (4-amino-quinazolin-6-yl)-3-pyridin- 2-YL-PYRAZOLE-1-SULFONIC acid dimethylamide (which is prepared by coupling 6-iodo-4- aminoquinazoline (the title compound of Example G above) with 1- (NN-DIMETHYL)- sulfamoyl-3-pyridin-2-yl-pyrazole-4-boronic acid (the title compound of Example 1 (d) above) in the same manner as described in Example L (e) above) in 10 mL CH3CN was added 0. 28 ML (2. 0 mmol) triethylamine, then 97 mg (0. 6 mmol) 5-methylthiophene-2- carbonyl chloride (Oakwood Products, Inc., West Columbia, SC) with stirring to give a yellow solution. This was heated to reflux overnight, then cooled, diluted with ethyl acetate, washed with IN NAOH, then a 5% solution of citric acid, then brine. The organic phase was dried, filtered and concentrated to form 5-methyl-thiophene-2- carboxylic acid [6-(1-DIMETHYLSULFAMOYL-3-PYRIDIN-2-YL-LH-PYRAZOL-4-YL)-QUINAZOLIN-4- yl]-amide, a yellow solid, which was used in the next step without further purification ; m/z : 520 [M+H] +. 5-Methyl-thiophene-2-carboxylic acid [6- (1-dimethylsulfamoyl-3-pyridin-2-yl- LH-PYRAZOL-4-YL)-QUINAZOLIN-4-YL]-AMIDE was then deprotected in the same manner as described in Example 2 to produce the title COMPOUND. 1H-NMR (300 MHz, DMSO- d6, 8) : 8. 56 (s, 1H), 8. 67 (dd, J= 2 Hz, 4 Hz, 1H), 8. 25 (d, J= 2 Hz, 1H), 8. 15 (s, 1H), 8. 01 (m, 1H), 7. 99 (m, 1H), 7. 92 (d, J= 8 Hz, 1H), 7. 86 (d, J= 8 Hz, 1H), 7. 76 (d, J= 2 Hz, 1H), 7. 55 (t, J= 8 Hz, 1H), 7. 40 (d, J= 8 Hz, 1H), 6. 90 (m, 1H), 2. 50 (s, 3H) ; m/z : 413 [M+H] +.

Reference： [1]Patent: WO2004/72033,2004,A2 .Location in patent: Page 53

48
[ 31555-59-6 ]
[ 906096-11-5 ]
C₁₃H₁₁NO₄S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In dichloromethane; at 20℃;	Step A:; To an ice-cold suspension of 5-methyl-2-thiophenecaboxylic acid (304 mg, 2.14 mmol) in dichloromethane (10 mL) was added oxalyl chloride (0.18 mL, 2.14 mmol) dropwise. Then the ice-water bath was removed and the mixture was stirred for 1 h. To the above solution was added 2-amino-3-hydroxybenzoic acid hydrobromide (0.50 g, 2.14 mmol) followed by triethylamine (1.20 mL, 8.56 mmol). The resulting reaction mixture was stirred at room temperature overnight. The reaction was quenched with water (50 mL). The reaction mixture was extracted with dichloromethane. The aqueous layer was extracted with dichloromethane (2×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to afford a yellow solid. The crude was dissolved in toluene (5 mL) and the solution was treated with p-toluenesulfonic acid monohydrate (464 mg, 2.44 mmol). The reaction mixture was then heated at 95 C. under nitrogen for 5 h. The reaction was cooled down to room temperature, poured into water and extracted with dichloromethane. The organic layer was separated, washed with water, brine, dried over Na2SO4, filtered and concentrated to a yellow solid. The crude material was purified by recrystallization from methanol to afford the desired product (111 mg, 26%) as an off-white solid: 1H NMR (500 MHz, DMSO-d6) delta 7.83-7.80 (m, 1H), 7.75-7.70 (m, 2H), 7.58-7.55 (m, 1H), 7.37-7.32 (m, 1H), MS (ESI+) m/z 260 (M+H).

Reference： [1]Patent: US2006/183769,2006,A1 .Location in patent: Page/Page column 62

49
[ 31555-59-6 ]
[ 906096-12-6 ]
C₁₃H₁₀ClNO₄S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In dichloromethane; at 20℃;	Step A:; To an ice-cold suspension of 5-methyl-2-thiophenecarboxyl acid (400 mg, 2.14 mmol) in dichloromethane (20 mL) was added oxalyl chloride (0.21 mL, 2.14 mmol) dropwise followed by a few drops of DMF. Then the ice-water bath was removed and the reaction mixture was stirred for 1 h. To the above solution was added 2-amino-3-hydroxybenzoic acid hydrobromide (0.50 g, 2.14 mmol) followed by triethylamine (1.19 mL, 8.56 mmol). The resulting reaction mixture was stirred at room temperature overnight. The reaction was quenched with 1 N HCl (20 mL). The reaction mixture was extracted with dichloromethane. The aqueous layer was extracted with dichloromethane (2×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to afford a yellow solid. The crude was dissolved in toluene (5 mL) and the solution was treated with p-toluenesulfonic acid monohydrate (619 mg, 3.25 mmol). The reaction mixture was then heated to reflux under nitrogen for 3 h. The reaction was cooled down to room temperature, poured into water and extracted with dichloromethane. The organic layer was separated, washed with water, brine, dried over Na2SO4, filtered and concentrated to a yellow solid. The crude material was recrystallized from methanol to afford the desired product (198 mg, 48%) as an off-white solid (78 mg, 12%): 1H NMR (500 MHz, DMSO-d6) delta 8.20 (d, J=2.1 Hz, 1H), 7.84 (d, J=3.7 Hz, 1H), 7.83 (d, J=2.2 Hz, 1H), 7.06 (dd, J=3.7, 1.1 Hz, 1H), 3.17 (s, 3H), MS (ESI+) m/z 293 (M+H).

Reference： [1]Patent: US2006/183769,2006,A1 .Location in patent: Page/Page column 64

50
[ 119256-40-5 ]
[ 31555-59-6 ]
5-Methyl-thiophene-2-carboxylic acid (4.6-difluoro-benzothiazol-2-yl)-amide [ No CAS ]